FindTrial
Sign In

An open-label, multicenter protocol providing pegylated interferon alfa 2-a PEGASYS as monotherapy or in combination with ribavirin COPEGUS for patients with chronic hepatitis C who have partecipated in previous Roche protocols.

An open-label, multicenter protocol providing pegylated interferon alfa 2-a PEGASYS as monotherapy or in combination with ribavirin COPEGUS for patients with chronic hepatitis C who have partecipated in previous Roche protocols.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001718-15-IT
Enrollment
750
Registered
2007-02-06
Start date
2004-12-27
Completion date
Unknown
Last updated
2012-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C MedDRA version: 6.1 Level: PT Classification code 10019744

Interventions

Trade Name: L03AB11-Peginterferone alfa-2A Product Name: peginterferone alfa-2A Pharmaceutical Form: Solution for injection INN or Proposed INN: Peginterferon alfa-2a Current Sponsor code: NV 17590 C

Sponsors

ROCHE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Austria, Germany, Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026